New pill combo takes on hard-to-treat lung cancer in major trial

NCT ID NCT07174908

Recruiting now Disease control Sponsor: InxMed (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests two oral drugs (IN10018 and D-1553) against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. About 400 participants who have not had prior treatment will be randomly assigned to one of the two options. The main goal is to see if the new drug combination delays cancer progression better than current therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IN10018 and D-1553 (oral drugs)
What this could lead to: If successful, this combination could offer a new targeted treatment option for people with a specific type of lung cancer (KRAS G12C mutation), potentially improving how long they live without their cancer growing.
What could go wrong: This is a phase 3 trial, but it's still experimental. The new combination may not work better than current standard therapy, and side effects are unknown. Results may not apply to all lung cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, China
First Affiliated Hospital of Gannan Medical University
NOT_YET_RECRUITING

Gannan, Jiangxi, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, China
Hunan Cancer Hospital
NOT_YET_RECRUITING

Changsha, Hunan, China
Jiangsu Cancer Hospital
RECRUITING

Nanjing, Jiangsu, China
Shanghai Chest Hospital
RECRUITING

Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of Nanchang University
NOT_YET_RECRUITING

Nanchang, Jiangxi, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, China
The First Affiliated Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, China
Union Hospital Tongji Medidcal College Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310005, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.